A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients With Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Latest Information Update: 10 Apr 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Acral lentiginous melanoma; Malignant melanoma
- Focus Biomarker; Therapeutic Use
- 15 Dec 2023 Status changed from active, no longer recruiting to discontinued.
- 07 Jan 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 07 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.